GI CANCERS

DPTX3186 gains FDA fast track status, promising a novel treatment for gastric cancer with potential for significant patient impact.

Zanidatamab plus chemotherapy shows significant survival benefits for HER2-positive gastroesophageal adenocarcinoma, potentially transforming first-line treatment options.

The FDA accepts 177Lu-edotreotide for GEP-NETs, showcasing significant survival benefits over everolimus in recent trials.

FDA fast-tracks alnodesertib and irinotecan for ATM-negative metastatic colorectal cancer, showing promising efficacy and safety in early trials.

A new treatment combination shows significant promise for patients with resistant gastrointestinal stromal tumors, improving survival rates and tolerability.

New findings reveal promising antitumor responses in HER2-positive esophagogastric adenocarcinoma with a novel chemoimmunotherapy approach.

A phase 1b trial reveals the safety and potential efficacy of combining PolyPEPI1018 vaccine with TAS-102 in treating advanced colorectal cancer.

The EDGE-Gastric trial reveals promising results for domvanalimab and zimberelimab in treating advanced gastric cancer, showcasing durable efficacy and manageable safety.

A novel combination therapy shows promising results for advanced esophageal squamous cell carcinoma, achieving high response rates and manageable safety.

Experts discuss the CUTNETs collaborative's efforts to enhance surgical care and standardize treatment for neuroendocrine tumors across multiple centers.

AI transforms cancer treatment by personalizing care and enhancing patient-provider communication, revolutionizing how patients manage their health.

A groundbreaking study reveals promising efficacy and safety of 212Pb-DOTAMTATE for treating neuroendocrine tumors, paving the way for future trials.

Experts discuss the impact of dose escalation in treating neuroendocrine tumors, highlighting recent trials and collaborative research efforts for improved patient outcomes.

The FDA designates daraxonrasib as an orphan drug for pancreatic cancer, targeting RAS mutations with promising trial results.

A new analysis reveals unique symptom burdens and quality of life challenges in younger patients with neuroendocrine tumors, enhancing tailored care strategies.

GLP-1 receptor agonists show promise in treating various chronic conditions, but potential risks and unanswered questions remain for care of patients with NETs.

Jonathan Strosberg, MD, details findings with 212Pb-DOTAMTATE in patients with gastroenteropancreatic neuroendocrine tumors from the ALPHAMEDIX-02 trial.

A study reveals that obesity and sex significantly influence liver recurrence and survival rates in pancreatic cancer patients post-surgery.

The COMPETE trial reveals ITM-11 significantly improves progression-free and overall survival in patients with gastroenteropancreatic neuroendocrine tumors.

A groundbreaking study reveals 212Pb-DOTAMTATE's promising efficacy and safety in treating advanced gastroenteropancreatic neuroendocrine tumors.

New data reveals VCN-01 enhances survival and response rates in metastatic pancreatic cancer when combined with standard chemotherapy, promising future trials.

Emerging research highlights the rising incidence of early-onset neuroendocrine tumors, revealing unique challenges and symptom burdens in younger patients.

Nivolumab plus ipilimumab shows significant progression-free survival benefits in metastatic colorectal cancer, establishing a new standard of care.

New research compares transarterial embolization and chemoembolization for treating neuroendocrine liver metastases, revealing unexpected safety differences.

Bemarituzumab combined with mFOLFOX6 shows promising overall survival benefits in advanced FGFR2b-overexpressing gastric cancer, despite safety concerns.